[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649173":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":27,"centralContacts":32,"locations":37,"responsibleParty":92,"collaborators":94,"id":96,"slug":97,"hasResults":98,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":24,"eligibilityCriteria":102,"healthyVolunteers":103,"sex":104,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":24,"studyType":110,"phases":111,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":40,"whyStopped":24,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":150},{"fullName":5,"class":6},"BioNTech SE","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"BNT162b2 Vaccine","EXPERIMENTAL","Participants will receive a single injection containing variant-adapted BNT162b2 on Day 1.",[13],"Biological: BNT162b2 Vaccine",{"label":15,"type":16,"description":17,"interventionNames":18},"Tdap Vaccine","ACTIVE_COMPARATOR","Participants will receive a single injection containing Tdap on Day 1.",[19],"Biological: Tdap Vaccine",[21,25],{"type":22,"name":9,"description":11,"armGroupLabels":23,"otherNames":24},"BIOLOGICAL",[9],null,{"type":22,"name":15,"description":17,"armGroupLabels":26,"otherNames":24},[15],[28],{"name":29,"affiliation":30,"role":31},"Pfizer CT.gov Call Center","Pfizer","STUDY_DIRECTOR",[33],{"name":29,"role":34,"phone":35,"phoneExt":24,"email":36},"CONTACT","1-800-718-1021","ClinicalTrials.gov_Inquiries@pfizer.com",[38,52,62,72,82],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":24},"Diablo Clinical Research, LLC dba Flourish Research","RECRUITING","Walnut Creek","California","94598","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-122.06496,37.90631,{"lat":50,"lon":49},{"facility":53,"status":40,"city":54,"state":55,"zip":56,"country":44,"countryCode":45,"cosmosGeoPoint":57,"geoPoint":61,"contacts":24},"Palm Springs Community Health Center","Miami Lakes","Florida","33014",{"type":47,"coordinates":58},[59,60],-80.30866,25.90871,{"lat":60,"lon":59},{"facility":63,"status":40,"city":64,"state":65,"zip":66,"country":44,"countryCode":45,"cosmosGeoPoint":67,"geoPoint":71,"contacts":24},"East-West Medical Research Institute","Honolulu","Hawaii","96814",{"type":47,"coordinates":68},[69,70],-157.85833,21.30694,{"lat":70,"lon":69},{"facility":73,"status":40,"city":74,"state":75,"zip":76,"country":44,"countryCode":45,"cosmosGeoPoint":77,"geoPoint":81,"contacts":24},"Duke Vaccine and Trials Unit","Durham","North Carolina","27703",{"type":47,"coordinates":78},[79,80],-78.89862,35.99403,{"lat":80,"lon":79},{"facility":83,"status":40,"city":84,"state":85,"zip":86,"country":44,"countryCode":45,"cosmosGeoPoint":87,"geoPoint":91,"contacts":24},"J. Lewis Research, Inc. \u002F Foothill Family Clinic","Salt Lake City","Utah","84109",{"type":47,"coordinates":88},[89,90],-111.89105,40.76078,{"lat":90,"lon":89},{"type":93,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[95],{"name":30,"class":6},"100649173","phase-4-a-study-to-learn-about-a-covid-19-vaccine-in-healthy-adults-18-through-64-years-of-age-100649173",false,"NCT07730450","A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age","A PHASE 4, RANDOMIZED, DOUBLE-BLIND, THIRD-PARTY-UNBLINDED STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF A BNT162B2 RNA-BASED, VARIANT-ADAPTED VACCINE CANDIDATE AGAINST SARS-COV-2 AND EVALUATE THE CIRCULATING SARS-COV-2 SPIKE PROTEIN LEVEL IN HEALTHY PARTICIPANTS 18 THROUGH 64 YEARS OF AGE","Key Inclusion Criteria\n\n\\- Healthy participants 18 through 64 years of age who do not have medical conditions that put them at a higher risk for severe COVID-19.\n\nKey Exclusion Criteria\n\n* Participants who tested positive for COVID-19 within 6 months (180 days) prior to Visit 1\n* Participants who have recently received a vaccine, or plan to receive a nonstudy COVID-19 or comparator vaccine during participation.\n\nThe complete list of inclusion and exclusion criteria are listed in the protocol.",true,"ALL","18 Years","64 Years",{"count":108,"type":109},200,"ESTIMATED","INTERVENTIONAL",[112],"PHASE4","The purpose of this study is to learn about the safety and effects of an updated COVID-19 vaccine (called BNT162b2) in adults 18 to 64 years of age.\n\nThis study is seeking participants who:\n\n* are medically stable\n* have not had a recent COVID-19 infection\n* have not had a recent vaccination\n* do not have medical conditions that increase their risk of complications from COVID-19\n\nAll participants in this study will randomly receive 1 injection into their arm of either:\n\n* BNT162b2 vaccine which targets COVID-19 and is selected for the 2026-2027 COVID-19 season, or\n* Tdap vaccine which targets tetanus, diphtheria, and pertussis (whooping cough).\n\nThe study team and participants will not know which injection they receive. We will evaluate safety and SARS-CoV-2 spike protein levels in people receiving each of these vaccines.\n\nParticipants will be in the study for about 12 months.",[115],"COVID-19 Vaccines",[117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,115,137,138,139,140],"Pneumonia","Pneumonia, Viral","Respiratory Tract Infections","Infections","Virus Diseases","Coronavirus Infections","Coronaviridae Infections","Nidovirales Infections","RNA Virus Infections","Lung Diseases","Respiratory Tract Diseases","COVID-19","mRNA Vaccines","Nucleic Acid-Based Vaccines","Vaccines, Synthetic","Recombinant Proteins","Proteins","Amino Acids, Peptides, and Proteins","Vaccines","Biological Products","Viral Vaccines","Antigens","Biological Factors","BNT162 Vaccine","2026-08-05",{"date":143,"type":144},"2026-08-07","ACTUAL",{"date":146,"type":144},"2026-07-23",{"date":148,"type":109},"2027-08-20",{"name":5,"class":6},5]